Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma

Brief Title

Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma

Official Title

Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma

Brief Summary

      Plaque radiotherapy is a common treatment for uveal melanoma. However, local failure has been
      reported in up to 20% of patients. We use intraoperative ultrasonography at plaque insertion
      and removal to evaluate plaque movement as a potential factor in local failure.

Detailed Description

      Episcleral plaque radiotherapy is a common treatment for uveal melanoma and results in local
      tumor control in most cases. However, local failure has been reported in a substantial
      proportion of patients. Since local failure greatly increases the risk of metastatic death,
      identifying and correcting the causes of local treatment failure are of paramount importance.
      Poor plaque localization is an important contributing factor to local failure. With the aid
      of intraoperative ultrasonography, most malpositioned plaques can be identified and
      readjusted at the time of plaque insertion. However, little is known about plaque movement
      during the 4-5 days of brachytherapy, which could also contribute to local failure. To
      address this question, we perform intraoperative B-scan ultrasonography at the time of
      iodine-125 radioactive plaque insertion and removal in uveal melanoma patients.

Study Type

Interventional

Primary Outcome

Plaque tilt using intraoperative ultrasonography

Condition

Uveal Melanoma

Intervention

Intraoperative ultrasonography

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Procedure

Estimated Enrollment

Start Date

July 2000

Completion Date

July 2007

Primary Completion Date

July 2007

Eligibility Criteria

        Inclusion Criteria:

          -  All patients with uveal melanoma treated with brachytherapy

        Exclusion Criteria:

          -  Ciliary melanoma

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

J W Harbour, MD, ,

Location Countries

United States

Location Countries

United States

Administrative Informations

NCT ID

NCT00459849

Organization ID

HRPO# 07-0092

Study Sponsor

Barnes Retina Institute

Study Sponsor

J W Harbour, MD, Principal Investigator, Washington University School of Medicine

Verification Date

May 2008